David M. Weiner,Robert E. Davis,Mark R. Brann,Carl-Magnus A. Andersson,Allan K. Uldam
申请号：
US16687467
公开号：
US20200323836A1
申请日:
2019.11.18
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonist may confer antipsychotic and ant dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
